Condition
Ramucirumab
Total Trials
4
Recruiting
1
Active
1
Completed
2
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 2 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
Trial Status
Completed2
Not Yet Recruiting1
Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07144995Not Yet Recruiting
MAIC of Fruquintinib Plus Paclitaxel Versus Ramucirumab Plus Paclitaxel in Advanced G/GEJ Adenocarcinoma
NCT06490055Completed
Predicting the Efficacy in Advanced Gastric Cancer.
NCT06490159Recruiting
Predicting Peripheral Neuropathy of Paclitaxel for Gastric Cancer
NCT03486379Completed
Folfiri as Third Line of Treatment
Showing all 4 trials